Huaan CNI Biomedicine ETF(159508.SZ)

Company Encyclopedia
View More
name
Huaan CNI Biomedicine ETF
159508.SZ
News
View More

WuXi AppTec faces another reduction in holdings by its major shareholder, with a cumulative cash-out of nearly 20 billion over 3 years

WuXi AppTec's controlling shareholder reduced their holdings by approximately 59.68 million shares between November 20, 2025, and January 5, 2026, cashing out nearly 20 billion yuan in total. This reduction was transferred to a well-known international investor, with the selling price ranging from 84.66 to 95.08 yuan per share, amounting to 5.4 billion yuan. After the reduction, the controlling shareholder's stake decreased to 16.211%. Affected by geopolitical factors and market fluctuations, WuXi AppTec's stock price rose over 90% by the end of 2025, but has recently seen a pullback. On January 7, the stock price slightly dropped to 98.41 yuan per share

Stheadline·
SH
603259
+0.93%
HK
02359
-0.98%
Stheadline·
SH
603259
+0.93%
HK
02359
-0.98%

Pharmaron Expands CRO Market Presence with Biortus Acquisition

Pharmaron Beijing Co., Ltd. has announced the acquisition of an 82.54% interest in Biortus, enhancing its presence in the CRO market. This acquisition, considered a connected transaction, was evaluated by comparing Biortus with four other industry companies, focusing on profitability. The move is expected to leverage Biortus' growth in revenue and profits. The latest analyst rating for Pharmaron's stock is a Buy with a HK$28.10 price target.

Tip Ranks·
HK
03759
+0.96%
SZ
300759
+1.31%
Tip Ranks·
HK
03759
+0.96%
SZ
300759
+1.31%

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

HSBC analyst Linda Shu has reaffirmed a Buy rating for Hangzhou Tigermed Consulting Co., Ltd. Class H, setting a price target of HK$54.00. The stock closed at HK$44.04. Shu, a 3-star analyst, has an average return of 8.0% and a 64.71% success rate. The overall analyst consensus for the company is a Strong Buy, with an average price target of €5.92, indicating a potential downside of -86.56%. CLSA also maintains a Buy rating with a target of HK$52.10.

Tip Ranks·
HK
03347
+2.47%
SZ
300347
-0.69%
Tip Ranks·
HK
03347
+2.47%
SZ
300347
-0.69%

News: Biokin Pharmaceutical launches Hong Kong IPO and is expected to be included in the Stock Connect

The biopharmaceutical company Sichuan Biokin Pharmaceutical has launched its Hong Kong IPO, planning to issue 8.63 million shares at a price of HKD 347.50 to HKD 389, with a maximum fundraising of HKD 3.36 billion. The subscription deadline is November 12, and the listing date is November 17. The company is already listed on the Shanghai Stock Exchange and qualifies for inclusion in the Hong Kong Stock Connect, allowing mainland investors to trade. The cornerstone investors for this issuance include well-known companies such as Bristol Myers Squibb, and the joint sponsors are top investment banks like Goldman Sachs and JP Morgan

BambooWorks·
SH
688506
+3.38%
BambooWorks·
SH
688506
+3.38%

05:08 ET Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30

Tigermed has been recognized as one of the Top 30 companies in the "2025 Forbes China Go-International Flagship Brands" list. This ranking, launched by Forbes China, highlights firms with significant international presence. Tigermed, a global clinical development services provider, operates over 180 offices worldwide and aims to enhance its global footprint and digital transformation while advancing China's pharmaceutical innovation. The company collaborates with over 3,600 clients, focusing on integrated R&D solutions in the biopharmaceutical sector.

prnewswire·
HK
03347
+2.47%
SZ
300347
-0.69%
prnewswire·
HK
03347
+2.47%
SZ
300347
-0.69%
© 2026 Longbridge｜Disclaimer